China Universal Asset Management Company’s Coherus Oncology CHRS Stock Holding History

China Universal Asset Management Company’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$34.4K	Sell	24,549 -1,976	-7%	-$3.23K	﹤0.01%	478
2026 Q1	$44.8K	Buy	26,525 +6,829	+35%	+$12.1K	﹤0.01%	463
2025 Q4	$28K	Buy	+19,696	New	+$28.7K	﹤0.01%	481
2024 Q4	–	Sell	-22,158	Closed	-$23K	–	503
2024 Q3	$23K	Buy	22,158 +8,679	+64%	+$11.9K	﹤0.01%	403
2024 Q2	$23.3K	Sell	13,479 -7,947	-37%	-$16K	﹤0.01%	389
2024 Q1	$51.2K	Buy	21,426 +8,546	+66%	+$21K	0.01%	411
2023 Q4	$42.9K	Buy	12,880 +10,454	+431%	+$28K	0.01%	384
2023 Q3	$9.07K	Buy	2,426 +1,193	+97%	+$5.51K	﹤0.01%	354
2023 Q2	$5.26K	Buy	1,233 +179	+17%	+$1.06K	﹤0.01%	364
2023 Q1	$7.21K	Buy	1,054 +264	+33%	+$2.05K	﹤0.01%	334
2022 Q4	$6.26K	Buy	790 +62	+9%	+$477	﹤0.01%	270
2022 Q3	$7K	Buy	+728	New	+$7.37K	﹤0.01%	232

Other funds holding CHRS

TGY2IT

Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

China Universal Asset Management Company's CHRS Position: Q2 2026 in Review

China Universal Asset Management Company reduced its Coherus Oncology (CHRS) stake by 7.4% in Q2 2026, selling an estimated $3.23K and leaving 24,549 shares worth $34.4K. The position accounts for ﹤0.01% of the portfolio, ranked #478.

China Universal Asset Management Company first reported a position in CHRS in Q3 2022 and has held it in 12 quarters since. The position peaked at $51.2K in Q1 2024. 85 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

China Universal Asset Management Company held 24,549 shares of Coherus Oncology worth $34.4K as of Q2 2026.
China Universal Asset Management Company sold 1,976 Coherus Oncology shares in Q2 2026, an estimated $3.23K.
Coherus Oncology made up ﹤0.01% of China Universal Asset Management Company's portfolio in Q2 2026, its #478 holding.
China Universal Asset Management Company first reported a position in Coherus Oncology in Q3 2022 and has held it in 12 quarters since.
China Universal Asset Management Company's Coherus Oncology position peaked at $51.2K in Q1 2024.
85 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.